Page last updated: 2024-08-21

quinazolines and amg 900

quinazolines has been researched along with amg 900 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bak, A; Bush, TL; Cee, VJ; Chung, G; Deak, HL; Dussault, I; Eden, P; Geuns-Meyer, S; Hodous, BL; Kendall, RL; McElroy, P; Nguyen, HN; Olivieri, PR; Patel, VF; Payton, M; Radinsky, R; Romero, K; Ross, S; Schenkel, LB; Stanton, M; Ziegler, B	1
Cheung, HK; Coxon, A; Crispino, JD; Hanestad, K; Juan, G; Marinaccio, C; Ninniri, MSS; Payton, M; Wayne, WC	1

Other Studies

2 other study(ies) available for quinazolines and amg 900

Article	Year
Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer research, 2010, Dec-01, Volume: 70, Issue:23 Topics: Adult; Animals; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Benzamides; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; HCT116 Cells; HeLa Cells; Histones; Humans; Mice; Mice, Nude; Mutation; Neoplasms; Organophosphates; Paclitaxel; Phosphorylation; Phthalazines; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Quinazolines; Xenograft Model Antitumor Assays	2010
Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes. Molecular cancer therapeutics, 2018, Volume: 17, Issue:12 Topics: Animals; Apoptosis; Aurora Kinases; Cell Cycle Checkpoints; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Female; G1 Phase; Humans; Leukemia, Myeloid, Acute; Megakaryocytes; Mice; Mitosis; Organophosphates; Phthalazines; Polyploidy; Protein Isoforms; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2018

Article

Year

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.

Cancer research, 2010, Dec-01, Volume: 70, Issue:23

Topics: Adult; Animals; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Benzamides; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; HCT116 Cells; HeLa Cells; Histones; Humans; Mice; Mice, Nude; Mutation; Neoplasms; Organophosphates; Paclitaxel; Phosphorylation; Phthalazines; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Quinazolines; Xenograft Model Antitumor Assays

2010

Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes.

Molecular cancer therapeutics, 2018, Volume: 17, Issue:12

Topics: Animals; Apoptosis; Aurora Kinases; Cell Cycle Checkpoints; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Female; G1 Phase; Humans; Leukemia, Myeloid, Acute; Megakaryocytes; Mice; Mitosis; Organophosphates; Phthalazines; Polyploidy; Protein Isoforms; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2018